Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency
Metagenomi Therapeutics, Inc. (Nasdaq: MGX) announced a scientific publication highlighting MG119-28, a proprietary compact CRISPR nuclease with superior genome editing efficiency compared to previously known nucleases. The research demonstrates structural and mechanistic features that improve editing in mammalian cells, supporting the company's pi…